Fierce Competition of R&D of KRAS G12C Inhibitors
Recently, the class 1 new drug "ZG19018 Tablets" of Suzhou Zelgen Biopharmaceuticals Co., Ltd. is approved for clinical use in China and the indications are: advanced malignant solid tumors with KRAS G12C mutation.
January 13, 2022
by PharmaSources/Yi
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company...
October 13, 2021
by prnasia
With the transaction exceeding 300 million US dollars reached, how is the exploration of Chinese inhibitor KRAS G12C?
On September 2, Innovent announced that it had reached a global exclusive licensing agreement with Genfleet. Innovent, as an exclusive partner of Genfleet, will obtain the right to develop and commercialize GFH925...
September 14, 2021
by PharmaSources/Yefenghong
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
Jacobio Pharmaceuticals today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.
August 3, 2021
by prnasia
Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer
InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong University School ...
June 25, 2021
by prnasia
FDA Approves Lumakras (sotorasib) for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AMGN today announced that the U.S. Food and Drug Administration (FDA) has approved Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
May 31, 2021
by drugs
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one
May 31, 2021
by fda.gov
FDA Grants Sotorasib Priority Review Designation for Advanced, Metastatic NSCLC
Amgen announced the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ...
February 19, 2021
by americanpharmaceuticalreview
Amgen Submits Sotorasib Marketing Authorization Application to EMA
Amgen announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, an investigational KRASG12C inhibitor, for the treatment of adult patients with previously treated KRAS G12C-mutated ...
December 28, 2020
by americanpharmaceuticalreview